ARID1A Gene Mutation clinical trials at UCSD

1 in progress, 0 open to eligible people

NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Sorry, in progress, not accepting new patients
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
La Jolla, California and other locations

Last updated: August 2025

NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer